Raphas microneedle passes US FDA's cGMP inspection

The company starts to accelerate to enter US market for acne treatment microneedle patch

Raphas' acne treatment microneedle patch product 
Raphas' acne treatment microneedle patch product 
Ye-Na Kim 1
2023-07-26 14:37:56 yena@hankyung.com
Bio & Pharma


South Korea's microneedle maker Raphas Co. announced on Wednesday that it has passed the Current Good Manufacturing Practice (cGMP) inspection by the US Food and Drug Administration (FDA) for its microneedle patch used in acne treatment medications.

With this recent FDA cGMP approval, Raphas has not only obtained the ability for mass production based on its droplet extension (DEN) technology but also gained recognition for the quality of its pharmaceutical products. 

Earlier in January, Raphas registered its acne treatment microneedle patch called "Killa ES" with the FDA using the original design manufacturer (ODM) approach and launched the product in the North American market through the US company Heyday in April.

Following the cGMP inspection approval and the successful launch of Killa ES, Raphas plans to release its brand-new acne treatment microneedle patch called RapMed-2303 in the North American market by the fourth quarter of this year. The company is also preparing to obtain approval for general pharmaceuticals as improved drugs in the South Korean market.

"With the successful inspection, the foundation for exporting microneedle patch medications to the North American market has been established," a Raphas source said. "We expect substantial sales increase in both the United States and Korea based on this achievement."

Write to Ye-Na Kim at yena@hankyung.com
#Raphas #Current Good Manufacturing Practice #cGMP #FDA #microneedle patch #droplet extension #Killa ES #ODM #RapMed-2303

Ildong Bioscience gets US FDA OK for probiotic raw materials

Ildong Bioscience gets US FDA OK for probiotic raw materials

South Korea's Ildong Bioscience on Thursday said two of its probiotic raw materials received the certification generally recognized as safe (GRAS) from the US Food and Drug Administration (FDA).Such certification is FDA recognition of a substance's safety as a raw material for food.The two bac

Huons’ 2% lidocaine gets approval from FDA

Huons’ 2% lidocaine gets approval from FDA

South Korean pharmaceutical firm, Huons Co., announced on Monday that it has secured another significant regulatory milestone in the US with the Food and Drug Administration's (FDA) approval for the Abbreviated New Drug Application (ANDA) for its 2% lidocaine injection 5mL vial. Lidocaine is a

Hanmi Pharm's Efinopegdutide gets Fast Track Designation from FDA

Hanmi Pharm's Efinopegdutide gets Fast Track Designation from FDA

Merck, known as MSD outside the United States and Canada, announced on Monday that Efinopegdutide, a technology transferred from the South Korean pharmaceutical company Hanmi Pharmaceutical Co., was granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatme

Celltrion gets FDA approval for Humira biosimilar CT-P17

Celltrion gets FDA approval for Humira biosimilar CT-P17

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Administration for its biosimilar of the autoimmune disease treatment drug Humira (adalimumab) called CT-P17 (brand name: Yuflyma).As a result, Celltrion

S.Korea's microneedle maker Raphas to enter US market

S.Korea's microneedle maker Raphas to enter US market

South Korea's microneedle maker Raphas Co. is expediting its entry into the American pharmaceutical market after entering the country's cosmetics sector, with its US-based sales company to start activity in June to expand the company's acne patch business. Raphas will also build as early

(* comment hide *}